Nobel laureate Honjo, Ono Pharma settle royalty suit
November 13, 2021
OSAKA (Jiji Press) — Nobel Prize winner Tasuku Honjo and Ono Pharmaceutical Co. settled Friday their lawsuit over patent royalties for cancer immunotherapy drug Opdivo.
The Osaka-based drugmaker will pay Honjo, special professor at Kyoto University, ¥5 billion in settlement and donate ¥23 billion to a fund the university will set up to support young researchers.
In June last year, Honjo filed a damages lawsuit against Ono with the Osaka District Court, demanding that the company pay about ¥26.2 billion.
Honjo claimed that Ono paid him only 1% of the settlement money it received from a U.S. firm in an Opdivo patent infringement litigation although the drugmaker should have offered 40%.
Ono rebutted that it had proposed to pay 40% of the money but Honjo turned it down. As a result, the company paid him 1% under the 2006 licensing terms, it said.
Honjo won the 2018 Nobel Prize in Physiology or Medicine, along with a U.S. scientist, for the basic research that led to the development of nivolumab, which Ono makes and sells as Opdivo.
The two sides entered into settlement talks in September, in the wake of the court’s advice to compromise.
“I want basic research supported for the long term by funds from companies capitalizing on scientific findings and achievements as well as goodwill donations,” Honjo said in a comment released after the settlement.
"Society" POPULAR ARTICLE
-
Akira Toriyama, Mangaka Known for ‘Dragon Ball’ ‘Dr. Slump,’ Dies at 68 (UPDATE 2)
-
Strong Earthquake Rocks near Tokyo; Saitama and Tochigi Prefectures Observe Lower 5 Quake on Japan’s Seismic Scale of 7 (UPDATE 1)
-
Fuji-Q Highland to Close Do-Dodonpa, Fastest Roller Coaster in the Industry; Enjoyed by 9.3 Million People Since Opening in 2001
-
Two Dead After Avalanche in Southwestern Hokkaido; Victims Believed to be Backcountry-Skiing Foreign Nationals (Update 1)
-
Spring Warmth in Central Tokyo; Winter Chill Expected at Early Next Week
JN ACCESS RANKING